Favorable Media Coverage Somewhat Unlikely to Impact C R Bard (BCR) Stock Price

News headlines about C R Bard (NYSE:BCR) have trended positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. C R Bard earned a daily sentiment score of 0.32 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 45.3317861877906 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

Several equities research analysts recently issued reports on BCR shares. Barclays increased their price objective on C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Jefferies Group reissued a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a research note on Thursday, September 14th. Needham & Company LLC reissued a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective for the company in a research note on Tuesday, December 26th. Finally, Cowen reissued a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $311.43.

Shares of C R Bard (NYSE BCR) remained flat at $$331.24 during trading on Friday. The stock has a market capitalization of $24,140.00, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C R Bard has a 1 year low of $223.02 and a 1 year high of $337.73.

C R Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The company had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. During the same period last year, the business earned $2.64 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. research analysts forecast that C R Bard will post 11.89 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.31%. The ex-dividend date was Thursday, December 7th. C R Bard’s dividend payout ratio (DPR) is presently 10.28%.

In other news, insider Timothy P. Collins sold 55,818 shares of the firm’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $322.03, for a total transaction of $17,975,070.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher S. Holland sold 38,242 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $334.04, for a total value of $12,774,357.68. The disclosure for this sale can be found here. Insiders have sold a total of 193,887 shares of company stock valued at $63,801,024 over the last ninety days. Company insiders own 0.80% of the company’s stock.

WARNING: “Favorable Media Coverage Somewhat Unlikely to Impact C R Bard (BCR) Stock Price” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://sportsperspectives.com/2018/01/07/favorable-media-coverage-somewhat-unlikely-to-impact-c-r-bard-bcr-stock-price.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply